Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RANI

Rani Therapeutics Holdings Inc

May 22 • 04:00PM ET

1.07

0.00 0.00 %

Healthcare • Biotechnology • USA • Micro • NASD

May 20, 11:02 AMAnalyst reaffirmations on RT-114 obesity progress drive RANI's 21% surge.

Peers: ORMP ENTX XERS LPCN GOSS

| Held by: VTI VXF IWC IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.41	Insider Own	21.98%	Shs Outstand	99.81M	Perf Week	-0.93%
Market Cap	132.45M	Forward P/E	-	EPS next Y	-0.22	Insider Trans	0.00%	Shs Float	77.88M	Perf Month	16.88%
Enterprise Value	99.93M	PEG	-	EPS next Q	-0.06	Inst Own	28.42%	Short Float	11.49%	Perf Quarter	-16.41%
Income	-29.44M	P/S	41.78	EPS this Y	50.00%	Inst Trans	-1.86%	Short Ratio	8.03	Perf Half Y	-38.86%
Sales	3.17M	P/B	3.76	EPS next Y	1.11%	ROA	-77.48%	Short Interest	8.95M	Perf YTD	-20.74%
Book/sh	0.28	P/C	3.04	EPS next 5Y	20.34%	ROE	-232.30%	52W High	3.87 -72.35%	Perf Year	65.10%
Cash/sh	0.35	P/FCF	-	EPS past 3/5Y	29.57% 11.92%	ROIC	-95.33%	52W Low	0.39 176.49%	Perf 3Y	-76.01%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 28.73%	Gross Margin	74.44%	Volatility	12.64% 8.90%	Perf 5Y	-
Dividend TTM	-	EV/Sales	31.52	EPS Y/Y TTM	58.49%	Oper. Margin	-1092.93%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.40	Sales Y/Y TTM	164.08%	Profit Margin	-929.09%	RSI (14)	55.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.40	EPS Q/Q	82.00%	SMA20	9.02%	Beta	0.79	Target Price	7.50
Payout	-	Debt/Eq	0.14	Sales Q/Q	893.02%	SMA50	10.09%	Rel Volume	0.65	Prev Close	1.07
Employees	71	LT Debt/Eq	0.09	Earnings	May 15 AMC	SMA200	-6.36%	Avg Volume	1.11M	Price	1.07
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.11% 51.82%	Trades		Volume	724,991	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Initiated	Lake Street	Buy	$9
Aug-02-24	Initiated	Oppenheimer	Outperform	$17
Jun-14-24	Initiated	Maxim Group	Buy	$15
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$10
Apr-17-23	Resumed	BTIG Research	Buy	$24
Oct-11-22	Initiated	UBS	Buy	$15
Jul-27-22	Initiated	H.C. Wainwright	Buy	$22
Jun-13-22	Initiated	Wedbush	Outperform	$28

May-15-26 04:05PM	Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition (GlobeNewswire) -9.97%
May-12-26 04:05PM	Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference (GlobeNewswire)
Apr-09-26 07:00AM	Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy (GlobeNewswire) -6.15%
Mar-26-26 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -5.26% -24.94%
Mar-25-26 04:53PM	Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization (GlobeNewswire) +7.55%
09:19AM	Loading…
09:19AM	What To Expect From Rani Therapeutics Holdings Inc (RANI) Q4 2025 Earnings (GuruFocus.com)
Mar-19-26 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Jan-28-26 07:00AM	Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer (GlobeNewswire)
Jan-24-26 08:45AM	Largest borrow rate increases among liquid names (TipRanks)
Jan-08-26 07:00AM	Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen (GlobeNewswire)
Nov-24-25 04:05PM	Rani Therapeutics to Participate in the Evercore Healthcare Conference (GlobeNewswire)
Nov-06-25 04:30PM	Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -9.20% -11.01%
Oct-30-25 08:00AM	Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill Capsule at ObesityWeek 2025 (GlobeNewswire) -12.65%
Oct-26-25 06:05AM	H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential (Insider Monkey)
Oct-23-25 04:05PM	Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors (GlobeNewswire) -13.46% -12.92%
04:01PM	Loading…
04:01PM	Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire)
Oct-17-25 01:12PM	Why Rani Therapeutics (RANI) Stock Is Soaring Friday? (GuruFocus.com) +248.27%
07:31AM	Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire)
07:30AM	Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing (GlobeNewswire)
Aug-07-25 04:05PM	Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire)
Jul-15-25 09:00AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering (GlobeNewswire) -38.92%
Jul-14-25 05:00AM	Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery (GlobeNewswire) +8.45%
May-19-25 08:00AM	Rani Therapeutics Announces Research Agreement with Chugai (GlobeNewswire) +9.27%
May-13-25 04:05PM	Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update (GlobeNewswire) -21.42% +15.59%
Apr-01-25 10:55AM	Q4 2024 Rani Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:05AM	Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Mar-31-25 07:15PM	Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript (Seeking Alpha) -7.35%
04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-26-25 04:05PM	Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill Capsule, to Subcutaneously Administered PG-102 (GlobeNewswire) -6.29%
Mar-25-25 06:00PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
04:05PM	Loading…
Feb-05-25 04:05PM	Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill HC (GlobeNewswire) +5.11% +14.58%
Nov-14-24 08:00AM	Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:05PM	Rani Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-17-24 08:00AM	Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist (GlobeNewswire)
Oct-15-24 08:30AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants (GlobeNewswire) -33.33%
Oct-13-24 06:01AM	Oppenheimer Predicts up to 740% Rally for These 2 Strong Buy Stocks (TipRanks)
Oct-08-24 04:05PM	Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire) +7.31%
Sep-03-24 04:05PM	Rani Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -7.50%
Aug-06-24 04:05PM	Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Jul-29-24 04:05PM	Rani Therapeutics to Participate in August Investor Conferences (GlobeNewswire)
Jul-22-24 08:30AM	Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering (GlobeNewswire)
Jun-24-24 07:00AM	Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment (GlobeNewswire)
May-16-24 10:15AM	UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating (MT Newswires)
May-14-24 08:00AM	Rani Therapeutics to Participate in May Investor Conferences (GlobeNewswire) -5.40%
May-09-24 08:00AM	Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill Capsule at Digestive Disease Week 2024 (GlobeNewswire) -5.17%
May-07-24 09:06PM	Rani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic Updates (GuruFocus.com)
May-06-24 09:55PM	RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024 (InvestorPlace) +5.73%
04:05PM	Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-21-24 09:45AM	Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:35AM	Q4 2023 Rani Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-24 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Mar-15-24 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +6.25%
Feb-05-24 08:00AM	Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) (GlobeNewswire) +5.73%
Dec-14-23 08:00AM	Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist (GlobeNewswire)
Dec-07-23 12:00PM	What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock (Zacks)
Nov-08-23 05:53PM	Rani Therapeutics Holdings Inc (RANI) Reports Q3 2023 Financial Results and Corporate Developments (GuruFocus.com)
04:05PM	Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Nov-01-23 04:05PM	Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-25-23 08:00AM	The RaniPill Capsule, Rani Therapeutics' Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study (GlobeNewswire)
Oct-19-23 04:05PM	Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study (GlobeNewswire)
Oct-12-23 04:05PM	Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (GlobeNewswire)
Sep-18-23 08:00AM	Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43) (GlobeNewswire)
Sep-07-23 04:05PM	Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies (GlobeNewswire)
Sep-06-23 08:00AM	Rani Therapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-11-23 04:05PM	Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire)
Aug-04-23 04:05PM	Rani Therapeutics to Participate in August Investor Conferences (GlobeNewswire)
Jun-21-23 08:00AM	Rani Therapeutics Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference (GlobeNewswire)
Jun-08-23 08:00AM	Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference (GlobeNewswire)
Jun-05-23 08:00AM	Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105 (GlobeNewswire)
Jun-01-23 08:00AM	Rani Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 08:00AM	Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference (GlobeNewswire)
May-24-23 08:00AM	Rani Therapeutics Appoints Kate McKinley as Chief Business Officer (GlobeNewswire)
May-17-23 09:50AM	2 Strong Buy Penny Stocks With Over 400% Upside on the Horizon (TipRanks) +12.25%
May-10-23 04:05PM	Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update (GlobeNewswire) -8.84%
Apr-26-23 06:46AM	Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) last week's 14% decline must have disappointed private companies who have a significant stake (Simply Wall St.)
Apr-25-23 08:00AM	Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-11-23 08:00AM	Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-23 07:12AM	Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 04:05PM	Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update (GlobeNewswire) -6.89%
Mar-16-23 04:05PM	Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire) +5.71%
Jan-09-23 08:30AM	Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment (GlobeNewswire)
Jan-05-23 04:05PM	Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update (GlobeNewswire) +8.12%
Dec-06-22 04:05PM	Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study (GlobeNewswire) +9.67%
Nov-17-22 05:30AM	Private companies among Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders, saw gain in holdings value after stock jumped 21% last week (Simply Wall St.)
Nov-10-22 05:25PM	Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-09-22 04:05PM	Rani Therapeutics to Present at the Stifel Healthcare Conference (GlobeNewswire)
Oct-28-22 09:55AM	Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Oct-24-22 08:30AM	Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update (GlobeNewswire) -10.03%
Sep-27-22 09:06AM	8 Best Stocks to Buy According to Billionaire Marc Lasry (Insider Monkey)
Sep-06-22 04:05PM	Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 11:47PM	Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock (GlobeNewswire) -25.89% +37.55%
Aug-10-22 05:45PM	Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:28PM	Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
04:28PM	Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update (GlobeNewswire)
04:23PM	Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis (GlobeNewswire)
Aug-08-22 08:30AM	Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinical Pipeline Development (GlobeNewswire)
Aug-03-22 07:48AM	Investors in Rani Therapeutics Holdings (NASDAQ:RANI) have made a return of 16% over the past year (Simply Wall St.)
May-11-22 04:05PM	Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update (GlobeNewswire) -5.75%
May-04-22 03:09PM	Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth (Simply Wall St.)

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Executive ChairmanMr. Mir A. Imran

CEO & DirectorMr. Talat Imran

Chief Financial OfficerMr. Svai S. Sanford

Chief Business OfficerMs. Kate McKinley M.B.A.

Chief Technical OfficerMr. Alireza Javadi Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
IMRAN MIR A	Director	Oct 23 '25	Buy	0.60	2,083,334	1,260,417	2,083,334	Oct 27 07:24 PM
South Cone Investments Limited	10% Owner	Oct 21 '25	Sale	2.77	4,000,000	11,074,000	2,379,194	Oct 22 06:57 PM
South Cone Investments Limited	10% Owner	Oct 20 '25	Sale	2.41	1,923,000	4,637,314	6,379,194	Oct 22 06:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RANI

Rani Therapeutics Holdings Inc

Upgrade your Finviz experience